Back

Phenomapping-derived tool to individualize the effect of sacubitril/valsartan in heart failure with preserved ejection fraction

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Tailored therapeutics advances in heart failure Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Jin Joo Park

Seoul National University Bundang Hospital, Seongnam (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail
Daprodustat in patients with heart failure and renal anemia: multicenter, open-label, randomized controlled study
Doctor Y. Singh (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Telemonitored standardized titration for heart failure with reduced ejection fraction, an open clinical cohort study.
Associate Professor N. Bergh (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
The in-hospital use of SGLT2i in heart failure with ischemic aetiology and recent acute coronary syndrome
Doctor A. D'Amato (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Effect of angiotensin converting enzyme inhibitors versus angiotensin receptor blockers on all-cause mortality in heart failure patients receiving quadruple guideline directed medical therapy
Assistant Professor A. Sahin (Canakkale, TR)
Abstract Slides Video
Presentation thumbnail
Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial
Doctor S. Chatur (Boston, US)
Abstract Slides

Access the full session

Session thumbnail
Tailored therapeutics advances in heart failure

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Machine learning does not improve risk prediction in heart failure in comparison to the PREDICT-HF model: derivation and validation in PARADIGM-HF and ATMOSPHERE
thumbnail
Congress Presentation
Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: the PARAGLIDE-HF Trial
thumbnail
Congress Presentation
Derivation and validation of a multicenter model to identify candidates for advanced HF therapies with high potential to achieve post-LVAD reverse cardiac remodeling

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources